Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium Laser

Vaginal Atrophy Clinical Trial

Official title:

Study of the Efficiency and Safety of Low-Intensity Neodymium Laser Radiation With a Nanosecond Pulse Duration for Treatment of the Vaginal Walls Atrophic Changes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05335317
• Other study ID #: TVALINNL-2019
• Status: Recruiting
• Phase: N/A
• Start date: April 18, 2022
• Est. completion date: September 1, 2024

Study information

• Verified date: March 2024
• Source: MeLSyTech, Ltd
• Contact: Ksenia V Shatilova, Ph.D.
• Phone: +79262792700
• Email: shatilova[@]melsytech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of study is characteristic of changes in the vaginal wall after treatment of neodymium laser radiation with a wavelength of 1064 nm. To assess the condition of the vaginal walls before and after laser treatment, the following methods will be used: vaginal health index, perineometry, measurement of the vaginal wall thickness by ultrasound, Doppler sonography of the vaginal walls vessels, optical coherence tomography, biopsy, cytological and immunocytochemical methods. The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality. Total up to 100 participants with and 20 participants without postmenopausal atrophy will be involved in the study. Participants will be divided into three groups: laser treatment (study group), topical hormones treatment (control group 1) and no treatment (control group 2) by 70, 30 and 20 participants in each group respectively. The time intervals between special tests and the tests themselves will be the same for all groups. Thus, a direct comparison between conventional treatment (topical hormones), laser treatment of the vaginal atrophy and normal condition without treatment will be made. The main hypothesis of the study is improvement in condition of the vaginal walls after laser treatment compared with the initial state of not less than thirty percent of participants, and improvement in condition on average compared with the control group.

Description:

The principle of participant distribution into groups is the main method of treatment of postmenopausal vaginal atrophy. Total up to 100 participants with and 20 participants without postmenopausal atrophy will be involved in the study. Participants will be divided into three groups: laser treatment (study group), topical hormones treatment (control group 1), and no treatment (control group 2) by 70, 30, and 20 participants in each respectively. The types of examination of each group are the same and include: - General methods: clinical blood analysis, clinical urine test, vaginal smear for flora, femoflor screen (method is intended for the study of vaginal microbiocenosis), cervical oncocytology test, extended colposcopy, pelvic ultrasound. - Special methods: filling out the questionnaire (King's Health Questionnaire), Vaginal Health Index, ultrasound for assessing blood vessels (Doppler sonography) and vaginal wall thickness, perineometry, optical coherence tomography (OCT), vaginal smear for immunocytochemical examination and cytology. The TREATMENT PROCEDURE of this study is the laser treatment of the vagina and vulva with a "Magic Max" laser with subsequent monitoring. Treatment Technique: Laser treatment procedure will be carried out in three stages. In total, three procedures will be performed with an interval of 4-6 weeks. Three follow-up visits will follow: 1, 3 (mandatory) and 6 (optional) months after the last procedure. During the procedure, the following sequence of actions will be performed: 1. st Stage - vaginal processing with a conical mirror handpiece, 2. nd Stage - vaginal processing with a corner mirror handpiece, 3. d Stage - external vulva and paraurethral region processing with a switched beam diameter handpiece. Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 nanoseconds (ns), the pause between pulses is 30 microseconds (us). The energy of one pulse is about 1 millijoule (mJ). The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth. The CONTROL PROCEDURE. Local hormone therapy with estriol will be used as a therapeutic tool for the control group. The course of treatment will be of 2 weeks of daily use, and then a maintenance therapy, when the suppository will be used of 2 times a week for 1.5-2 months to prevent symptoms. Participants of all groups will be tested with the general methods necessary to include the participant in the study at the first visit. For the laser treatment group: Studies will be carried out using special methods and then laser treatment of the vagina and vulva and paraurethral region will be performed during the 2nd, 3d, and 4th visits. Studies with special methods only will be performed during the 5th (1 month after the last procedure), 6th (3 months after the last procedure), and 7th (6 months after the last procedure) visits. For the control group 1 (hormonal treatment): Studies with special methods only will be performed during the 2nd, 3d, and 4th visits. Hormone therapy will begin from the 2nd visit. All subsequent visits will be carried out at the same time intervals as for the laser treatment group, using studies with special methods. The 3d visit will be in 4-6 weeks after the start of treatment, the 4th will be in 4-6 weeks after the 3d visit, the 5th - 1 month after the 4th, the 6th - 3 months after the 4th, the 7th - 6 months after the 4th. Thus, a direct comparison between conventional treatment (topical hormones) and laser treatment of the vaginal atrophy will be made during the treatment, as well as on follow-up visits in 1, 3 and 6 months after the end of each type of treatment. For the control group 2 Vaginal Health Index will be estimated only and OCT investigation with biopsy. The study will be carried out with the participation of several clinics: 1. Privolzhsky Research Medical University (main scientific coordinator, information for participant recruiting), 2. State-Funded Healthcare Institution of the Nizhny Novgorod region "Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko" (location of laser equipment, laser treatment and participant consultation, special tests, collection of material for cytological and immunocytochemical analysis, recruiting), 3. Municipal Hospital №35 of the Soviet District of Nizhny Novgorod (cytological and immunocytochemical analysis), 4. State-Funded Healthcare Institution of the Nizhny Novgorod region "Municipal Clinical Hospital №29" (information for participant recruiting, general tests to include participants in the study), 5. LLC "Clinic of modern technologies "SADKO" (recruiting, general tests to include participants in the study, location of laser equipment, laser treatment and participant consultation, special tests, collection of material for cytological and immunocytochemical analysis), 6. Medical Center "Imidzh Lab" (information for participant recruiting, general tests to include participants in the study), 7. LLC "Tonus" (information for participant recruiting, general tests to include participants in the study). All data obtained during the study will be transferred to the manufacturer of "MeLSyTech" Ltd. Statistics The analysis will be carried out both between groups of participants receiving different types of therapy (analysis of independent groups) and within groups at different time intervals (analysis of matched groups). Before performing statistical analysis of the data, the distribution type of the variables will be assessed. To assess the normality of distribution for each variable, histograms of frequency distributions will be visually evaluated, indicators of skewness, kurtosis, and the D'Agostino-Pearson normality test will be used. In addition to checking the type of distribution of variables, the equality of variances of the studied groups will be assessed using the methods of analysis of variance, in particular the Brown-Forsythe test. Methods of descriptive analysis will be used depending on the type of distribution of the variable. With a normal distribution, the mean (M) and standard deviation (SD) will be calculated. In case of an nongaussian distribution, the median (Me) and interquartile range will be calculated. Different algorithms of statistical analysis will be applied depending on the type of distribution of variables. Comparison of the paired and unpaired groups with a normal distribution, in case of the equality of the variances, will be carried out by the methods of analysis of variance ANOVA. Comparison of groups in pairs will be performed using the post-hoc method of posterior multiple comparisons (Tukey test). Comparison of groups in which variables do not follow the normal distribution will be carried out using the methods of nonparametric analysis of variations: the Kruskal-Wallis test (ANOVA tests) for independent groups and the Friedman test for matched groups. Dunn's multiple comparison test will be used to assess intergroup differences. Before assessing intergroup differences, the initial samples (1 visit) will be analyzed for identity using ANOVA or nonparametric Kruskal-Wallis tests (depending on the type of data). In case of significant differences in the samples, the search and removal of extremely deviating values (outliers) will be carried out. Differences will be considered statistically significant if the significance P values are <0.05.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: September 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age of 40-75 years, inclusive;
• Vaginal atrophy or 1st grade vaginal prolapse with atrophy, or lack of vaginal atrophy in case of control group 2;
• All participants have informed consent to conduct a course of procedures according to protocol, carry out follow-up visits, and conduct studies.

Exclusion Criteria:

• Age of under 40 and over 75 years old;
• History of oncological diseases;
• Active tuberculosis;
• Inflammatory diseases of the vulva and vagina including genital herpes in the acute stage;
• Urinary tract infections;
• Damage to the vaginal mucosa;
• Pregnancy;
• Tendency to photoallergy including taking photosensitizing drugs (diuretics, antihistamines, antipsychotics);
• Porphyria;
• Cardiac deficiency of 2-3 degrees;
• Chronic renal disease;
• Participants with greater than 1st grade vaginal prolapse;
• Women after childbirth up to 8 weeks;
• Participants who, according to the doctor, are not able to complete the study;
• Protocol non-compliance of laser exposure sessions;
• Voluntary refusal to participate in the study;
• Violation of recommendations for the management of the period after laser treatment;
• Adverse events that occurred during laser processing and research, and associated with them.
• The appearance of contraindications listed in the Exclusion criteria.

Related Conditions & MeSH terms

• Atrophy
• Postmenopausal Period
• Prolapse
• Uterine Prolapse
• Vaginal Atrophy
• Vaginal Prolapse

Intervention

Device:
• Laser Treatment
Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ. General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50% overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm (total handpiece length of 10 centimeter (cm), 20 treatment points along vagina), from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 100 milliseconds (ms), pause between packets of 50 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s. The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth.

Drug:
• Topical hormone estriol
Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.

Diagnostic Test:
• ?linical blood analysis
Taking blood from a vein for Clinical blood analysis (to include the participant in the study).
• ?linical urine test
Urine sampling for Clinical urine test (to include the participant in the study).
• Vaginal smear
Vaginal smear for flora investigation (to include the participant in the study), immunocytochemical examination and cytology (to evaluate procedure efficiency).
• Cervical oncocytology test.
Cervical smear for oncocytology test (to include the participant in the study).
• Extended colposcopy
Extended colposcopy is performed under a microscope using a Lugol to determine external changes in the epithelium in order to determine atrophy and pathologies of the cervix and vaginal vault (dysplasia, erosion, cancer, etc.) (to include the participant in the study).
• Pelvic ultrasound
Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).

Other:
• King's Health Questionnaire
The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).

Diagnostic Test:
• Vaginal Health Index
Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. pH (potential of hydrogen) will be investigated by test-lines paper (to evaluate procedure efficiency).
• Ultrasound investigation
Ultrasound investigation with General Electric Voluson E8 Expert for assessing blood vessels (Doppler sonography) and vaginal wall thickness measurement (to evaluate procedure efficiency).
• Perineometry
Pressure force of vaginal walls measurement with IEASE device (to evaluate procedure efficiency).
• Optical coherence tomography
Optical non-invasive method of investigation vaginal mucus morphological and functional condition.
• Biopsy
Biopsy of the vaginal wall to assess the condition of the vaginal wall and compare the obtained data with the data of optical coherence tomography.
• Femoflor screen
Femoflor screen for the study of vaginal microbiocenosis, specifically for the detection of the pathogens, opportunistic flora and normal flora and their qualitative and quantitative evaluation (to include the participant in the study).

Locations

Country	Name	City	State
Russian Federation	State-Funded Healthcare Institution of the Nizhny Novgorod region "Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko"	Nizhny Novgorod

Sponsors (1)

Lead Sponsor	Collaborator
MeLSyTech, Ltd

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Mean Change from Baseline of "General Health Perceptions" Score on the King's Health Questionnaire	Participants answer question: Q1. How would participant describe her health at the present? Answers = Points: Very good=1, Good=2, Fair=3, Poor=4, Very poor=5. Score = ((Score to Q1 - 1)/4) x 100	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Incontinence Impact" Score on the King's Health Questionnaire	Participants answer question: Q2. How much do participant think her bladder problem affects her life? Answers = Points: Not at all=1, A little=2, Moderately=3, A lot=4. Score =((Score to Q2 - 1)/3) x 100	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Role Limitations" Score on the King's Health Questionnaire	Participants answer questions: A. Does participant's bladder problem affect her household tasks? (cleaning, shopping etc) B. Does participant's bladder problem affect her job, or her normal daily activities outside the home? Answers = Points: Not at all=1, Slightly=2, Moderately=3, A lot=4. Score =(((Scores to Q 3A + 3B) - 2)/6) x 100	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Physical Limitations" Score on the King's Health Questionnaire	Participants answer questions: A Does participant's bladder problem affect her physical activities (e.g. going for a walk, running, sport, gym etc)? B. Does participant's bladder problem affect her ability to travel? C. Does participant's bladder problem limit her social life? D. Does participant's bladder problem limit her ability to see and visit friends? Answers = Points: Not at all=1, Slightly=2, Moderately=3, A lot=4. Score =(((Scores to Q 4A + 4B) - 2)/6) x 100	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Social Limitations" Score on the King's Health Questionnaire	Participants answer questions: A Does participant's bladder problem affect her physical activities (e.g. going for a walk, running, sport, gym etc)? B. Does participant's bladder problem affect her ability to travel? C. Does participant's bladder problem limit her social life? D. Does participant's bladder problem limit her ability to see and visit friends? Answers = Points: Not at all=1, Slightly=2, Moderately=3, A lot=4. [If 5C >/= 1] Score =(((Score to Q 4C + 4D + 5C) - 3)/9) X 100 [If 5C = 0] Score =(((Score to Q 4C + 4D) - 2)/6) x 100	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Personal Relationships" Score on the King's Health Questionnaire	Participants answer questions: A. Does participant's bladder problem affect her relationship with her partner? B. Does participant's bladder problem affect her sex life? C. Does participant's bladder problem affect her family life? Answers = Points: Not Applicable=0, Not at all=1, Slightly=2, Moderately=3, A lot=4.; [If 5A+5B >=2]Score =(((Scores to Q 5A + 5B) - 2)/6) x 100 [If 5A+5B =1] Score =(((Scores to Q 5A + 5B) - 1)/3) x 100 [If 5A+5B =0] Treat as missing value	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Emotions" Score on the King's Health Questionnaire	Participants answer questions: A. Does participant's bladder problem make she feel depressed? B. Does participant's bladder problem make she feel anxious or nervous? C. Does participant's bladder problem make she feel bad about herself? Answers = Points: Not at all=1, Slightly=2, Moderately=3, Very much=4. Score =(((Score to Q 6A + 6B + 6C) - 3)/9) X 100	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Sleep / Energy" Score on the King's Health Questionnaire	Participants answer questions: A. Does participant's bladder problem affect her sleep? B. Does participant's bladder problem make she feel worn out and tired ? Answers = Points: Never=1, Sometimes=2, Often=3, All the time=4. Score =(((Scores to Q 7A + 7B) - 2)/6) x 100	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Severity Measures" Score on the King's Health Questionnaire	Participants answer questions: Do participant do any of the following? A. Wear pads to keep dry? B. Be careful how much fluid she drink? C. Change her underclothes because it gets wet? D. Worry in case she smell? Answers = Points: Never=1, Sometimes=2, Often=3, All the time=4. Score =(((Scores to Q 8A + 8B + 8C + 8D) - 4)/12) x 100	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of "Bladder Problems" Score on the King's Health Questionnaire	Participants answer questions: What participant's bladder problems are and how much they affect participant? From the list below participant chooses only those problems that she have at present. Participant leave out those that don't apply to she.; FREQUENCY: going to the toilet very often NOCTURIA: getting up at night to pass urine URGENCY: a strong and difficult to control desire to pass urine URGE INCONTINENCE: urinary leakage associated with a strong desire to pass urine STRESS INCONTINENCE: urinary leakage with physical activity eg. coughing, running NOCTURNAL ENURESIS: wetting the bed at night INTERCOURSE INCONTINENCE: urinary leakage with sexual intercourse WATERWORKS INFECTIONS BLADDER PAIN Answers = Scores: Omitted=0, A little=1, Moderately=2, A lot=3.	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of Pressure at Rest with IEASE Device	Measurement is a part of perineometry. Pressure at rest will be measured with IEASE device as inner function, in millimeter of mercury column (mmHg). Participants will be asked to hold the IEASE device bulb in normal condition of vagina without added pressure.	2nd visit (before any treatment);1 month after 4th visit (after the end of any treatment), 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of Maximum Pressure at Contraction with IEASE Device	Measurement is a part of perineometry. Maximum pressure at contraction will be measured with IEASE device as inner function, in millimeter of mercury column (mmHg). Participants will be asked to hold the IEASE device bulb with maximum pressure they can.	2nd visit (before any treatment);1 month after 4th visit (after the end of any treatment), 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of Constant Pressure Contraction Duration with IEASE Device	Measurement is a part of perineometry. Pressure at contraction will be measured with IEASE device as inner function, in millimeter of mercury column (mmHg).; Participants will be asked to hold the IEASE device bulb for as long as they can with maximum pressure. The researcher will monitor the time from the beginning of contraction with maximum pressure to the moment when the pressure will decrease. Duration of constant pressure contraction will be measured with a stopwatch in seconds (s).	2nd visit (before any treatment);1 month after 4th visit (after the end of any treatment), 3 months after 4th visit, and 6 months after 4th visit
Other	Mean Change from Baseline of Basal Cells Percentage in Vaginal Smear	Part of a cytological test. Vaginal smear is stained by Romanowsky. The investigator counts 100 cells in aliquot with 100x magnification and records the proportion of basal cells. Parameter will be measured in percentages (%).	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 1 month after 4th visit (after the end of any treatment), 3 months after 4th visit
Other	Mean Change from Baseline of Parabasal Cells Percentage in Vaginal Smear	Part of a cytological test. Vaginal smear is stained by Romanowsky. The investigator counts 100 cells in aliquot with 100x magnification and records the proportion of parabasal cells. Parameter will be measured in percentages (%).	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 1 month after 4th visit (after the end of any treatment), 3 months after 4th visit
Other	Mean Change from Baseline of Intermediate Cells Percentage in Vaginal Smear	Part of a cytological test. Vaginal smear is stained by Romanowsky. The investigator counts 100 cells in aliquot with 100x magnification and records the proportion of intermediate cells. Parameter will be measured in percentages (%).	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 1 month after 4th visit (after the end of any treatment), 3 months after 4th visit
Other	Mean Change from Baseline of Superficial cells Percentage in Vaginal Smear	Part of a cytological test. Vaginal smear is stained by Romanowsky. The investigator counts 100 cells in aliquot with 100x magnification and records the proportion of superficial cells. Parameter will be measured in percentages (%).	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 1 month after 4th visit (after the end of any treatment), 3 months after 4th visit
Other	Mean Change from Baseline of Keratinization Index in Vaginal Smear	Part of a cytological test. Vaginal smear is stained by Romanowsky. Parameter will be assessed in the five non-overlapping fields of view with magnification 400x as the ratio of the number of superficial cells to the number of all cells * 100. An average value will be calculated for each participant. Parameter will be measured in percentages (%).	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 1 month after 4th visit (after the end of any treatment), 3 months after 4th visit
Other	Mean Change from Baseline of CK14 (Cytokeratin 14) Percentage in Vaginal Smear	Immunocytochemical examination. Histological preparation prepared by liquid-based cytology and stained according to the standard immunohistochemical protocol. Expression will be assessed in the 3-5 non-overlapping fields of view as the ratio of the number of positive-stained cells to the number of all cells * 100. An average value will be calculated for each participant. Parameter will be measured in percentages (%).	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 1 month after 4th visit (after the end of any treatment), 3 months after 4th visit
Other	Mean Change from Baseline of Vaginal Wall Thickness by Ultrasound Scaled Image	Measurement is a part of ultrasonography. Thickness will be measured with US-device. The vaginal probe will be inserted into the posterior fornix of the vagina, the thickness of the vaginal wall will be determined by the distance between the inner surface of the mucosa and adventitia, in millimeters (mm).	2nd visit (before any treatment);1 month after 4th visit (after the end of any treatment), 3 months after 4th visit, and 6 months after 4th visit
Primary	Mean Change from Baseline of Vaginal Health Index Score	Vaginal Health Index will be investigated by clinical examination for vagina: A. Vaginal elasticity (Characteristic=Points: Non=1, Poor=2, Fair=3, Good=4, Excellent=5), B. Vaginal secretions (None=1; S?ant, thin yellow=2; Superficial, thin white=3; Moderate, thin white=4; Normal (white)=5), C. Epithelial mucous membrane (Petechiae noted before contact=1, Bleeding with light contact=2, Bleeds with scraping, Not friable thin epithelium=4, Normal=5), D. Vaginal hydration (None, surface inflamed=1, None, surface nod inflamed=2, Minimal=3, Moderate=4, Normal=5), E. pH (potential of hydrogen) will be investigated by test-lines paper (=6.1=1, 5.6-6.0=2, 5.1-5.5=3, 4.7-5.0=4, =4.6=5).; Score=A+B+C+D+E	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 4th visit (4-6 weeks after 3d visit) - the end of any treatment; 1 month after 4th visit, 3 months after 4th visit, and 6 months after 4th visit
Primary	Mean Change from Baseline of Periodic Acid Schiff Reaction Percentage in Vaginal Smear	Part of a cytological test. Histological preparation prepared by liquid-based cytology and stained according to the instructions of the Periodic Acid Schiff kit. The investigator counts 100 cells in field of view with 400x magnification and records the proportion of cells with diffuse and granular staining. Parameter will be measured in percentages (%).	2nd visit (before any treatment); 3d visit (4-6 weeks after 2nd visit); 1 month after 4th visit (after the end of any treatment), 3 months after 4th visit
Primary	Mean Change from Baseline of Resistive Index by Doppler Sonography	Measurement is a part of ultrasonography. Resistive Index will be measured with US-device. The Resistive Index (RI) is calculated by the following equation: RI = (PSV - EDV) / PSV, where PSV is peak systolic velocity and EDV is end-diastolic velocity, in relative units.	2nd visit (before any treatment);1 month after 4th visit (after the end of any treatment), 3 months after 4th visit, and 6 months after 4th visit